The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries

The Global Retinoblastoma Study Group

Summary

Background Retinoblastoma is the most common intraocular cancer worldwide. There is some evidence to suggest that major differences exist in treatment outcomes for children with retinoblastoma from different regions, but these differences have not been assessed on a global scale. We aimed to report 3-year outcomes for children with retinoblastoma globally and to investigate factors associated with survival.

Methods We did a prospective cluster-based analysis of treatment-naive patients with retinoblastoma who were diagnosed between Jan 1, 2017, and Dec 31, 2017, then treated and followed up for 3 years. Patients were recruited from 260 specialised treatment centres worldwide. Data were obtained from participating centres on primary and additional treatments, duration of follow-up, metastasis, eye globe salvage, and survival outcome. We analysed time to death and time to enucleation with Cox regression models.

Findings The cohort included 4064 children from 149 countries. The median age at diagnosis was 23·2 months (IQR 11·0–36·5). Extraocular tumour spread (cT4 of the cTNMH classification) at diagnosis was reported in five (0·8%) of 636 children from high-income countries, 55 (5·4%) of 1027 children from upper-middle-income countries, 342 (19·7%) of 1738 children from lower-middle-income countries, and 196 (42·9%) of 457 children from low-income countries. Enucleation surgery was available for all children and intravenous chemotherapy was available for 4014 (98·8%) of 4064 children. The 3-year survival rate was 99·5% (95% CI 98·8–100·0) for children from high-income countries, 91·2% (89·5–93·0) for children from upper-middle-income countries, 80·3% (78·3–82·3) for children from lower-middle-income countries, and 57·3% (52·1–63·0) for children from low-income countries. On analysis, independent factors for worse survival were residence in low-income countries compared to high-income countries (hazard ratio 16·67; 95% CI 4·76–50·00), cT4 advanced tumour compared to cT1 (8·98; 4·44–18·18), and older age at diagnosis in children up to 3 years (1·38 per year; 1·23–1·56). For children aged 3–7 years, the mortality risk decreased slightly (p=0·0104 for the change in slope).

Interpretation This study, estimated to include approximately half of all new retinoblastoma cases worldwide in 2017, shows profound inequity in survival of children depending on the national income level of their country of residence. In high-income countries, death from retinoblastoma is rare, whereas in low-income countries estimated 3-year survival is just over 50%. Although essential treatments are available in nearly all countries, early diagnosis and treatment in low-income countries are key to improving survival outcomes.

Funding Queen Elizabeth Diamond Jubilee Trust.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction Retinoblastoma is the most common cause of death from eye cancer worldwide. Early diagnosis and prompt treatment can save a child’s life and the eye globe, with useful vision retained in selected cases. Being a rare malignancy, data on retinoblastoma outcomes are sparse, especially from low-income and middle-income countries. Most evidence is from treatment centres in high-income countries, although patients in high-income countries of North America, Europe, and Oceania combined represent less than 10% of global cases, whereas more than 80% of patients with retinoblastoma reside in low-income and middle-income countries in Africa, Asia, and Latin America.

In a single-centre study done in the USA (1994–2014), the retinoblastoma survival rate was reported to reach 99% (mean follow-up 4–8 years, depending on age group); in a single-centre study done in the UK (2002–14), it was reported to reach 100% (mean follow-up 5 years); and in a single-centre study done in Japan (1984–2016), it was reported to reach 95% (10-year overall survival), with most deaths occurring from trilateral retinoblastoma in all three studies. In low-income countries, survival rates are significantly lower: 60% (3-year survival) in a single-centre study done in Uganda (2009–19), 53% (follow-up time not indicated) in a single-centre study done in Senegal (2006–10), and 24% (10-year survival) in a single-centre study done in Nepal (1998–2008), with the majority of deaths in all three studies occurring from metastatic spread.

We previously reported the clinical characteristics of a global sample of children with retinoblastoma at the time...
Research in context

Evidence before this study
A literature search was done on PubMed from database inception to October, 2020, with the search terms “retinoblastoma”; and country name (eg, “Germany”) according to the World Bank list of countries. No date or language restrictions were applied. We included all original studies in which patients with retinoblastoma were evaluated. Publications were identified from 92 countries, with the vast majority of studies being from single retinoblastoma centres. Three articles by the American Joint Committee on Cancer Ophthalmic Oncology Task Force, all using the same cohort of patients, were published in 2020, comparing the outcome of treatment for retinoblastoma from 14 countries with different national income levels, none of which were low-income countries. Compared with high-income countries, mortality was 10·3-times higher for upper-middle-income countries and 9·3-times higher for lower-middle-income countries. We found no study investigating retinoblastoma outcomes on a global scale. Using PubMed and EMBASE, we also did a systematic review of all original studies reporting data on patients with retinoblastoma in African countries from Jan 1, 1989, to Dec 31, 2019. We used no language barriers. Following removal of duplicate entries, and screening of titles, abstracts, and the full text, we identified 44 original manuscripts from 24 of 54 countries in Africa. Reported survival rates ranged from 23% (Zimbabwe) to 100% (Egypt).

Added value of this study
This prospective cluster-based analysis reports 3-year outcomes of 4064 treatment-naive patients with retinoblastoma recruited in 2017 from 149 countries, including 41 African countries. It is estimated that this cohort represents approximately half of all new children diagnosed with retinoblastoma worldwide in 2017. Our findings show that in high-income countries retinoblastoma is a curable disease with nearly 100% survival, whereas in low-income countries survival after 3 years is just over 50%. Life-saving treatments were reported to be available in nearly all countries. Risk factors for this huge disparity in survival included the income level of the country of residence (low income vs high income), extracocular retinoblastoma at diagnosis, and older age at diagnosis (up to age 3 years).

Implications of all the available evidence
This study reports a huge global inequity in the prognosis of retinoblastoma in children. It provides evidence for action at national and international levels, including the WHO Global Initiative for Childhood Cancer, which aims to provide leadership and technical assistance to governments to develop high-quality childhood cancer programmes to improve survival and reduce suffering.

Methods
Study design and participants
This study adhered to the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement and the STRengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. This prospective cluster-based analysis followed up the cohort of 4351 children with retinoblastoma from 153 countries who presented to 278 treatment centres worldwide in 2017 (known as the Global Retinoblastoma Presentation Study). Details of the Global Retinoblastoma Presentation Study have been reported previously. In brief, during 2017–18, all known retinoblastoma centres across the world were contacted to form a global network. Centres involved in the diagnosis and treatment of patients with retinoblastoma were eligible to participate. The Global Retinoblastoma Presentation Study was a 1-year cross-sectional analysis that included all treatment-naive patients with retinoblastoma who presented to participating centres from Jan 1, 2017, to Dec 31, 2017, and who were treated or offered treatment for retinoblastoma. Following the Global Retinoblastoma Presentation study, which focused on clinical and epidemiological data at the time of diagnosis, all centres were invited to participate in a prospective analysis to report 3-year outcomes of patients from the original sample.

Participating centres were asked to submit information about primary and additional treatments, duration of follow-up, metastasis, eye globe salvage, and survival outcome. Information about the impact of the COVID-19 pandemic was also requested, as the pandemic emerged during the study period. All data were combined with the previously reported presentation data, including sex, age at diagnosis, laterality, familial retinoblastoma, and clinical tumour, node, metastasis, and heredity (cTNMH) stage.

Using the Global Retinoblastoma Study Group network, we also attempted to contact additional treatment centres that had not previously participated in the Global Retinoblastoma Presentation Study. New or existing centres that added new patients were asked to submit both the presentation data and the outcome data. All participating centres were asked to submit the completed forms in early 2020; however, because of the COVID-19 pandemic, the first form was received on July 3, 2020, and the last on March 31, 2021. For each form received, a process of data quality assurance was done, as previously described. Information on sex, the
patient’s country of residence, laterality, and death status at last follow-up (including unknown) was obligatory for a patient to be included.

This study was approved by the Institutional Review Board of the London School of Hygiene & Tropical Medicine (London, UK), which granted a waiver of informed consent. Participating centres applied for and received local ethics approval.

Data analysis
Analyses were done with R software (version 3.5.2). For survival analysis, all-cause mortality was used. Time from diagnosis to death was summarised by Kaplan-Meier curves. The analysis of time from diagnosis to enucleation (or exenteration) accounted for the competing risk of death, as patients who die with an intact eye globe present a special type of censoring. We used the standard approach of computing cumulative incidence curves for enucleation, adjusted for the competing risk of death. These curves provide consistent estimates of the proportion of patients who will undergo enucleation by a given time, accounting for prior death. In the case of bilateral eye globe loss, the first event was used for analysis.

For both time to death and time to enucleation, the association with potential risk factors or protective factors was analysed with Cox regression models. Smoothing splines were fitted for continuous factors to assess possible non-linear associations with risk. When such associations were found, they were replaced by linear splines for ease of interpretation. The knot locations for the linear splines were fixed on the basis of the smoothing splines for ease of interpretation. The knot locations for the linear splines were fixed on the basis of the smoothing spline analysis. The proportionality assumption of the Cox regression model was checked with Schoenfeld residuals.

All models included as potential risk or protective factors the economic grouping of the patient’s country,14 primary tumour stage (cT) and hereditary (H) category according to the eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual,15 age at diagnosis, and indicators for sex, laterality, and familial retinoblastoma. Age at diagnosis was found to have a non-linear relationship with both survival and eye globe salvage. The preliminary analyses were done with smoothing splines, and the subsequent analyses with linear splines are shown in the appendix (pp 1–2). All analyses were clustered by treatment centre nested within the patient’s country of residence. Robust standard errors, reflecting the clustering, were used to compute two-tailed p values and 95% CIs. Initial p values were presented, also after correction with Bonferroni’s method (multiplied by 13, the number of terms in each Cox model).

Missing values in the risk factors and protective factors were imputed as the most common value (for categorical variables) or the median value (for age at diagnosis) within the patient’s economic group. To account for missing outcome data, the analyses used inverse probability weighting, assuming data were missing at random.20 The probability of having data was estimated separately for each outcome by fitting a logistic regression model using the same factors listed above as predictors. Linear relationships to all factors were assumed in these models. Missing data for any of the categorical variables defined an additional category, so that the model accounted for the fact that patients with any of these missing data might also be more likely to have missing data on outcomes. Missing age at diagnosis was handled by assigning the average age in place of the missing values for age, and including an indicator for those missing the predictor. Patients declared to be alive or have an unknown death status and a follow-up time of zero were treated as missing the outcome.

Sensitivity analyses were done to ascertain whether the above decisions had an effect on the findings. These analyses included the use of inverse probability weights, imputation of missing factors versus deletion, the simple imputation versus multiple imputation from marginal distributions, extending the declaration of missing survival outcomes to participants with a follow-up of 1 month or less, and the possibility that the relationship of survival or eye globe salvage to age at diagnosis differs by hereditary status.

Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results
Of the 4351 patients included in the Global Retinoblastoma Presentation Study, 59 were excluded from the present analysis because of unavailable data, misdiagnosis, unmet inclusion criteria, or duplicate reporting, and 333 opted out as the corresponding centres did not want to participate in the study. An additional 105 newly recruited patients were added to the cohort. Overall, the study cohort therefore comprised 4064 treatment-naive patients, residing in 149 countries, who presented to 260 treatment centres worldwide in 2017, and received or were offered treatment for retinoblastoma (figure 1). 480 (11.8%) of 4064 children were from low-income countries, 1791 (44.1%) were from lower-middle-income countries, 1151 (28.3%) were from upper-middle-income countries, and 642 (15.8%) were from high-income countries. Asia had 2112 (52.0%) of 4064 cases, Africa had 958 (23.6%), Europe had 483 (11.9%), Latin America and the Caribbean had 309 (7.6%), North America had 182 (4.5%), and Oceania had 20 (0.5%).

The median age at diagnosis was 23·2 months (IQR 11·0–36·5), 1827 (45·0%) of 4064 patients were girls, 2809 (69.1%) of 4064 presented with unilateral disease, and 194 (4.9%) of 3958 patients had familial retinoblastoma. The most common cTNMH categories were cT3 (1824 [47·3%] of 3858), N0 (3164 [79·3%]
Global Retinoblastoma Presentation Study
278 centres reported 43551 patients from 153 countries (28 low-income countries, 44 lower-middle-income countries, 37 upper-middle-income countries, 44 high-income countries)

21 centres opted out; 333 patients from 17 centres (4 low-income countries, 5 lower-middle-income countries, 5 upper-middle-income countries, 3 high-income countries)

21 centres excluded 59 patients from 16 countries (2 low-income countries, 10 lower-middle-income countries, 2 upper-middle-income countries, 2 high-income countries)

48 missing charts
4 not treatment naive
2 reported twice
5 misdiagnosed

17 existing centres reported 52 new patients from 14 countries (2 low-income countries, 5 lower-middle-income countries, 5 upper-middle-income countries, 2 high-income countries)

4 new centres reported 53 new patients from 4 countries (1 lower-middle-income country, 3 high-income countries)

260 centres reported 4064 patients from 149 countries (26 low-income countries, 42 lower-middle-income countries, 36 upper-middle-income countries, 45 high-income countries)

Global Retinoblastoma Outcome Study
260 centres reported 4064 patients from 149 countries (26 low-income countries, 42 lower-middle-income countries, 36 upper-middle-income countries, 45 high-income countries)

Death was reported in 519 (12.8%) of 4064 patients. 146 (30.4%) of 480 patients were from low-income countries, 276 (15.4%) of 1791 were from lower-middle-income countries, 92 (8.0%) of 1151 were from upper-middle-income countries, and five (0.8%) of 642 were from high-income countries (table 1). 472 (90.9%) of 519 deaths were from retinoblastoma and 18 (3.5%) of 519 deaths were from high-income countries (table 1). 472 (90.9%) of 519 deaths were from retinoblastoma and 18 (3.5%) of 519 deaths were from high-income countries (table 1).

For the entire cohort, the 1-year survival rate was 90.7% (95% CI 89.8–91.6), the 2-year survival rate was 86.2% (85.1–87.3), and the 3-year survival survival rate was 84.5% (83.3–85.7). The 1-year, 2-year, and 3-year survival rates by national income level and by clinical stage at presentation are shown in the appendix (p 6). In low-income countries, the survival rate declined from 74.4% (95% CI 70.3–78.8) at 1 year to 57.3% (52.1–63.0) at 3 years, in lower-middle-income countries it declined from 88.4% (86.8–90.0) at 1 year to 80.3% (78.3–82.3) at 3 years, in upper-middle-income countries it declined from 95.1% (93.8–96.4) at 1 year to 91.2% (89.5–93.0) at 3 years, whereas in high-income countries it declined from 99.8% (99.5–100.0) at 1 year to 99.9% (98.8–100.0) at 3 years. Overall, for cT1-cT3, the survival rate was 90.5% or higher at 3 years, whereas for cT4 it declined from 55.0% (95% CI 50.8–59.6) at 1 year to 31.9% (27.6–36.9) at 3 years.

For new or recurring tumours, additional main treatments included intravenous chemotherapy (1311 [32.4%] of 4043), enucleation (1052 [26.0%]), laser or cryotherapy (995 [24.6%]), intra-ophthalmic artery chemotherapy (421 [10.4%]), or intravitreal chemotherapy (343 [8.5%]). Various types of radiotherapy were given to 195 (4.8%) of 4043 patients. Transformation to palliative therapy after initial intent to cure was reported in 18 (0.4%) of 4043 children, and treatment abandonment after initial treatment was reported in 155 (3.8%) patients.

The Kaplan-Meier survival estimate for the cohort, stratified by national income level, is shown in figure 2. For the entire cohort, the 1-year survival rate was 90.7% (95% CI 89.8–91.6), the 2-year survival rate was 86.2% (85.1–87.3), and the 3-year survival survival rate was 84.5% (83.3–85.7). The 1-year, 2-year, and 3-year survival rates by national income level and by clinical stage at presentation are shown in the appendix (p 6). In low-income countries, the survival rate declined from 74.4% (95% CI 70.3–78.8) at 1 year to 57.3% (52.1–63.0) at 3 years, in lower-middle-income countries it declined from 88.4% (86.8–90.0) at 1 year to 80.3% (78.3–82.3) at 3 years, in upper-middle-income countries it declined from 95.1% (93.8–96.4) at 1 year to 91.2% (89.5–93.0) at 3 years, whereas in high-income countries it declined from 99.8% (99.5–100.0) at 1 year to 99.9% (98.8–100.0) at 3 years. Overall, for cT1-cT3, the survival rate was 90.5% or higher at 3 years, whereas for cT4 it declined from 55.0% (95% CI 50.8–59.6) at 1 year to 31.9% (27.6–36.9) at 3 years.
Table 2 summarises the results of the clustered and weighted Cox proportional hazards models for survival. Both the income level of the country of residence (low income vs high income; hazard ratio 16–67 [95% CI 4.76–50.00]) and extraocular retinoblastoma at diagnosis (cT4 vs cT1; 8–98 [4.44–18.18]) were found to be associated with all-cause mortality. On analysis of age at diagnosis, for children aged 0–4 years, the risk of enucleation increased as a function of age, and then steadily decreased (p=0.0039). The incidence of enucleation was 63.1% (95% CI 61.4–64.8) at 1 year, 66.8% (65.1–68.5) at 2 years, and 69.0% (67.4–70.7) at 3 years (appendix p13).

Table 3 summarises the clustered and weighted Cox proportional hazards model for enucleation. Of the variables included in the analysis, primary tumour category (cT1 compared to cT2, cT3, or cT4) was found to be associated with a lower risk of enucleation as an outcome. On analysis of age at diagnosis, for children aged 0–4 years, the risk of enucleation increased as a function of age, and then steadily decreased (p=0.0039).
Children with unilateral retinoblastoma were more likely to have enucleation than children with bilateral disease. Other variables, including national income level, sex, family history of retinoblastoma, and hereditary status did not achieve significance. Sensitivity analyses were done (appendix pp 14–17) as outlined in the Methods, all of which showed little change from the primary analysis.

None of the deaths that occurred during 2020 (20 [39%] of 519) and none of the enucleations done during this period (40 [1.5%] of 2677) were associated with the COVID-19 pandemic or a delay in treatment because of the pandemic.

Discussion

This study shows that a large disparity exists in the survival rate of children with retinoblastoma depending on the economic level of their country of residence. The largest gap, a difference of nearly 17 times, was found between children from high-income countries and low-income countries. In high-income countries, retinoblastoma is considered a curable disease, and death is a rare event, whereas we found that in low-income countries just over 50% of children with retinoblastoma remained alive 3 years after diagnosis.

At the time of diagnosis, 40% of children from low-income countries compared with less than 1% from high-income countries had extraocular tumour spread, and children with an extraocular tumour had a nearly ten-times increased risk of dying compared to those with early intraocular disease. However, low-income status remained a major risk factor for death independently of the stage at diagnosis. Variations in management options by country income level are a possible contributing factor. Enucleation and intravenous chemotherapy, which can save a child’s life, were readily available in nearly all centres and countries. However, we previously reported differences in the availability of sophisticated treatments and investigation facilities in low-income and middle-income countries (such as MRI, targeted chemotherapy, radiotherapy, and focal treatments). Another possibility is that children in low-income countries present with a more biologically aggressive form of disease, a suggestion that had emerged from our presentation data.

Age at diagnosis independently predicted survival, although its impact was not as significant as the other factors. The risk of death increased until 3 years of age, remained the same for children aged 3–7 years, and then decreased. The latter change in slope, however, was not significant, possibly due to the small number of patients in this age group. Retinoblastoma is believed to develop through a benign retinoma stage, which is typically transient. It is possible that in children who were diagnosed after the age of 3 years, there was initially a longer retinoma phase, which failed to become fully inactive, gradually becoming larger. At a later age, it eventually escapes the senescence route and begins to develop increasing grades of anaplasia. These tumours might be less advanced than a rapidly transforming retinoma. This hypothesis is speculative, however, and requires further investigation.

The AJCC Ophthalmic Oncology Task Force reported outcomes of patients diagnosed with retinoblastoma in 14 countries. The 5-year survival rate was 99% for patients residing in high-income countries, 89% for those residing in upper-middle-income countries, and 90% for those residing in lower-middle-income countries. Of the study cohort, 41% of patients were from high-income countries, substantially more than the estimated global incidence in this economic group, and no patients from low-income countries were included. In 2010, a systematic review reported survival after retinoblastoma in 48 low-income and middle-income countries. Patients from high-income countries were not included, and many of the analysed countries have since migrated their income level classification. Moreover, a survival analysis was not done but instead a global estimate was given for each country without indicating the length of survival.
Reported survival rates were 40% in low-income countries, 77% in lower-middle-income countries, and 79% in upper-middle-income countries. We recently did a systematic literature search of the PubMed and EMBASE databases (unpublished data), including clinical case series of retinoblastoma in African countries from Jan 1, 1989, to Dec 31, 2019, and identified only 44 original reports from 24 of 54 countries in Africa during this period. Survival rates ranged widely, from 23% in Zimbabwe to 100% in Egypt. We are not aware of any other large-scale multinational studies that have investigated survival after retinoblastoma.

In the present study, enucleation or exenteration of at least one eye was reported in approximately two-thirds of the cohort, and 3% of patients lost both eyes in an attempt to save their life. In a recent study by the AJCC Ophthalmic Oncology Task Force,16 based on a cohort reported earlier,55% of patients underwent primary or secondary enucleation. Neither exenteration surgery nor the rate of bilateral enucleation were reported.

In our study, loss of an eye was not related to the income level of the patient’s country. Preserving an eye, even with relatively poor vision, is desirable, but not at the cost of the patient’s country. Preserving an eye, even with the rate of bilateral enucleation were reported. Moreover, genetic testing is not readily available in many countries, and rarely available in low-income countries.1

The main factor associated with eye globe salvage was tumour stage at presentation. Children with cT2–T4 retinoblastoma were less likely to have their eye salvaged than children with cT1. The hazard ratios for stages cT2, cT3, and cT4 did not show a gradual increase; rather, the highest hazard ratio was for cT3 (7.51; 95% CI 4.58–12.31). Possible explanations for the relatively lower hazard ratio for children with cT4 tumours are death before enucleation and palliation by chemotherapy only.

Age was another important predictor of eye globe salvage, showing a non-linear relationship with the risk of enucleation, increasing until age 4 years, and then decreasing. Further investigation of the number of cT3 and cT4 cases (data not shown), for which enucleation was a common treatment option, showed no apparent relationship with the age-stratified globe salvage model, suggesting that other factors might be of importance. Further investigation of the relationship between age at diagnosis and risk of enucleation is warranted.

Patients in this study were enrolled in 2017, and treated and followed up until a closing date of March 31, 2021. COVID-19, which was first detected in China in December, 2019, and subsequently developed into a pandemic, unexpectedly changed medical priorities and policies profoundly throughout the world, potentially affecting patients in our cohort. A previous survey, done in March to April, 2020, involving retinoblastoma specialists from 194 treatment centres in 94 countries, concluded that a shift in health-care resources and COVID-19 pandemic policies across the world might negatively affect children, especially those with new retinoblastomas.23 These concerns, however, were not confirmed in the present study, and suggest that our
Table 3: Cluster-weighted Cox proportional hazards models for eye globe salvage at 3 years in 4064 new patients with retinoblastoma diagnosed in 149 countries in 2017

| Income level of country of residence | Coefficient | Robust standard error | Z score | p value (corrected) | HR (95% CI) |
|-------------------------------------|-------------|-----------------------|---------|-------------------|-------------|
| Low income                          | Ref         | 0·007                 | 0·022   | 3·22              | 0·0009 (0·0117) | 1·00         |
| Lower-middle income                 |             |                      |         |                   |             |
| Upper-middle income                 |             |                      |         |                   |             |
| High income                         |             |                      |         |                   |             |
| All ages                            |             |                      |         |                   |             |
| HR per month                        | 0·007       | 0·002                 | 3·22    | 0·0009 (0·0117)   | 1·01 (1·00–1·01) |
| HR per year                         | 0·084       | 0·024                 | 3·22    | 0·0009 (0·0117)   | 1·09 (1·04–1·14) |
| Age >6 years                        |             |                      |         |                   |             |
| HR per month                        | 0·012       | 0·003                 | 3·598   | 0·003 (0·034)     | 0·99 (0·98–1·00) |
| HR per year                         | 0·144       | 0·036                 | 3·598   | 0·003 (0·034)     | 0·87 (0·81–0·93) |
| Laterality                          |             |                      |         |                   |             |
| Unilateral                          | Ref         |                      |         |                   | 1·00         |
| Bilateral                           | -0·428      | 0·142                 | -3·010  | 0·002 (0·026)     | 0·65 (0·49–0·86) |
| Primary tumour                      |             |                      |         |                   |             |
| cT1                                 | Ref         |                      |         |                   | 1·00         |
| cT2                                 | 1·024       | 0·226                 | 4·529   | <0·0001 (<0·0001) | 2·78 (1·79–4·34) |
| cT3                                 | 2·021       | 0·252                 | 8·027   | <0·0001 (<0·0001) | 7·54 (4·61–12·36) |
| cT4                                 | 1·510       | 0·318                 | 4·748   | <0·0001 (<0·0001) | 4·53 (2·43–8·45) |
| Sex                                 |             |                      |         |                   |             |
| Male                                | Ref         |                      |         |                   | 1·00         |
| Female                              | 0·077       | 0·059                 | 1·290   | 0·197 (0·99)      | 1·08 (0·96–1·21) |
| Family history of retinoblastoma    |             |                      |         |                   |             |
| Yes                                 | Ref         |                      |         |                   | 1·00         |
| No                                  | 0·299       | 0·178                 | 1·678   | 0·093 (0·99)      | 1·35 (0·95–1·91) |
| Hereditary retinoblastoma           |             |                      |         |                   |             |
| Non-hereditary                      | Ref         |                      |         |                   | 1·00         |
| Hereditary§                          | -0·121      | 0·124                 | -0·975  | 0·330 (0·99)      | 0·89 (0·70–1·13) |

HR=hazard ratio. *Overall, 797 observations were dropped from the eye globe salvage analysis because of missing data. **Hereditary refers to bilateral or trilateral retinoblastoma, positive family history, or positive blood HR11 mutation (H11 in cTNMH).

findings might be generalised, and do not represent a biased global outcome of patients with retinoblastoma in response to the COVID-19 pandemic.

The data presented here highlight the importance of the four pillars of the WHO Global Initiative for Childhood Cancer (CURE-ALL): centres of excellence and care networks, universal health coverage, regimens for management, and evaluation. Improved care networks and universal health coverage will promote early presentation and diagnosis. Expansion of centres of excellence and improved management regimens will address best management practice. Together with monitoring and evaluation, this will improve survival outcomes for children with retinoblastoma in low-income and middle-income settings. Datasets such as this can help establish global norms as called for in the WHO Global initiative for Childhood Cancer and lead to refinement and standardisation of locally appropriate management regimens to improve outcomes. The high response rate and degree of collaboration shown by this project raises the possibility of a live clinical data repository. Such a live collaboration could, in time, provide guidance on evidence-based management.

Our study has several strengths. First, it is, to the best of our knowledge, the largest and most geographically comprehensive study on retinoblastoma outcomes to date. Second, patients were prospectively followed up from presentation for a median time of nearly 3 years, a duration in which most events (ie, death and enucleation) occur. Third, the data were analysed by methods that take into account clustering, and tested with several sensitivity analyses, showing that the initial methodology selections were appropriate, and that our findings represent real-world outcomes of patients with retinoblastoma.

The main limitation of this study is that this cohort is based on the original convenience sample of the Global Retinoblastoma Presentation Study; however, the original sample comprised an estimated half of new cases that presented to treatment centres in most countries in 2017. We have shown that most patients of the missing half are from low-income and middle-income countries, and that the capture rate falls within the national income level category. Some of these patients, especially those from low-income countries, never reach a treatment centre, and they probably stand no chance of survival. Of the cohort, 45% of patients were girls. On a recent analysis of the global dataset, no evidence of sex predilection was found, but there was a possibility of gender discrimination in favour of boys who are brought to treatment centres in some parts of Asia. Because of the large size and geographical spread of the cohort, the obtained data related to treatments (available per country and given de facto) were limited to the type of treatment, without further details about the specific treatment protocol, complications, and related side-effects. Similarly, treatment refusal was reported to occur or not, before or after initial treatment was given, with no further details, and therefore no related subanalyses were done. Information about the impact of COVID-19 was limited as it was based on a survey addressing the caregivers in the treatment centres. Children lost to follow-up before the pandemic could potentially have been affected by the pandemic, data for which were not available to us. Nevertheless, it is our assumption that the impact of the COVID-19 pandemic on this cohort of patients was negligible. Age at diagnosis was not linearly linked to survival risk. The best fitting models were used for analysis, but they too were statistical approximations. Age, however, had only a minimal impact compared to the other variables.
inequality in mortality from retinoblastoma persists. In high-income countries, nearly 100% of children with retinoblastoma survive, whereas in low-income countries just over 50% remain alive 3 years after diagnosis, if brought at all to receive treatment. Around three in 100 children with retinoblastoma still lose both eyes. Better awareness of the early signs of retinoblastoma, improving access to timely diagnosis, and implementing existing guidelines and treatment recommendations aimed at children in low-income and middle-income countries are crucial to improving retinoblastoma outcomes worldwide. Notably, life-saving treatment was available in nearly all participating centres irrespective of the country of residence. Findings of the present study provide an evidence base for prioritisation and planning for the WHO Global Initiative for Childhood Cancer, which aims to assist governments to support building sustainable, high-quality childhood cancer programmes to improve survival and reduce suffering.

The Global Retinoblastoma Study Group

Albania: Donjeta B Alija, Alketa Tandili (University Hospital Centre “Mother Theresa”, Tirana). Angola: Luísa Paiva, Amelia DC Wime (National Ophthalmological Institute of Angola, Luanda). Argentina: Guillermo L Chantada, Adriana C Fandíño, Mariana Sgroi (Hospital JP Garralda, Buenos Aires). Armenia: Ruzanna Papyan, Gevorg Tamanyan (Yerevan State Medical University. Department of Oncology and Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after R. Yeloyan, Yerevan). Australia: Janey E Camuglia, Glen A Gole (Department of Ophthalmology, Queensland Children’s Hospital, Brisbane, Queensland). Antony Clark, Geoffrey C Lam (University of Western Australia, Perth Children’s Hospital, Perth, Western Australia). James E Elder, John D McKenzie, Sandra E Staffieri (Department of Ophthalmology, Royal Children’s Hospital, Parkville, Victoria). James E Elder (Department of Paediatrics, University of Melbourne, Parkville, Victoria), Michael M Jones (The Children’s Hospital at Westmead, Sydney, New South Wales), John D McKenzie (Department of Ocular Oncology, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria), Sandra E Staffieri (Center for Eye Research Australia, University of Melbourne, East Melbourne, Victoria), Rebecca Manudhane, David Sia (Women’s and Children’s Hospital, North Adelaide, South Australia), David Sia (Discipline of Ophthalmology and Visual Sciences, University of Adelaide and South Australian Institute of Ophthalmology, Adelaide, South Australia). Austria: Petra Ritter-Sovinz (Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology/Oncology, Medical University of Graz, Graz). Christof Schwab (Department of Ophthalmology, Medical University Graz, Graz). Azerbaijan: Ruhengiz Balayeva (Zarifa Aliyeva National Centre of Ophthalmology, Baku). Bangladesh: Zohora Khan (Dhaka Medical College Hospital, Dhaka). Murtuza Nuruddin, Soma R Roy (Chittagong Eye Infirmary & Superstein (CHU Sainte Justine, University of Montreal, Montréal), Katherine E Paton (The Hospital for Sick Children, Toronto), Patrick Hamel, Rosanne B. Hoang, Vincenzo LaCarrubba (National Institute of Cancer in Brazil, Rio de Janeiro), Luiz F Teixeira (Ophthalmology Department, Federal University of São Paulo, São Paulo). Iyad Al-Atrash, Paulina Bartoszek, Bénédicte G Brichard, Patrick Hamel, Rosanne Superstein (CHU Sainte Justine, University of Montreal, Montréal), Katherine E. Paton (University of British Columbia, Vancouver, British Columbia), Caron Strahlendorf (BC Children’s Hospital, Vancouver). Central African Republic: Jess Elio Koshi Komba Paet (Oncologe Pédiatre Responsable d’Unité de Bangui, Bangui). Chad: Harba Tyau-Tayu (Université Adam Barka, Adam Barka). Chile: Isabel Cavieres, Juan P López (Ophthalmology Department, Universidad de Chile, Santiago), Joaquin Oporto, Diego Ossandon (Clinica Alemana de Santiago, Universidad del Desarrollo, Santiago). China: Wensi Chen, Daniel Xue (Department of Pediatric Ophthalmology, Guangzhou Children’s Hospital and Guangzhou Women and Children’s Medical Center, Guangzhou). Wujiang, Yu Du, Kaijun Li (Department of Ophthalmology, the First Affiliated Hospital of Guangzhou Medical University, Nanning), Xunda Ji, Jing Tang (Department of Ophthalmology, Xinhua Hospital, Shanghai). Colombia: Rodrigo A Polania (Fundacion Clinica Valle del Lili, Cali). Côte d’Ivoire: Rokia C Berete (Ophthalmologic Department of the Teaching Hospital of Treichville, Abidjan). Croatia: Sanja Perić (University Hospital Centre Zagreb, Zagreb). Cuba: Ernesto Alemany-Rubio, Liudmila Gonzalez-Rodriguez (Instituto Cubano de Oftalmología “Ramón Pando Ferrer”, Marianao, Havana). Czech Republic: Rubolí Amat (Pediatric Ophthalmology Department, Children’s Hospital, Faculty of Medicine, Masaryk University Hospital Brno, Brno). Tomas Kepač (University Hospital Brno and St. Anna University Hospital/ICRC, Masaryk University, Brno), Pavel Pochop (Department of Ophthalmology for Children and Adults, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague), Karel Svojg (Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague). Denmark: Pernille A Gregersen (Department of Clinical Genetics, and Centre for Rare Disorders, Aarhus University Hospital, Aarhus). Estonia: Jeppe F Ursbäck (Department of Ophthalmology, Aarhus University Hospital, Aarhus). Dominican Republic: Margarita M Montero (Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo). Democratic Republic of the Congo: Aléna Buediongo, Jenny M Yanga (Cliniques Universitaires de Kinshasa, Université de Kinshasa, Kinshasa), Theophile B Kabesa Amani (Bukavu Eye Clinic - Bukavu Official University, Bukavu). Robert M Lukamba, Marcel N Numu (University Clinics of Lubumbashi, University of Lubumbashi, Lubumbashi). Ecuador: Doris A Calle Jara, Edwin G Villacis Chafla (Hospital del Niño Dr. Francisco De Icaza). Egypt: Sherif Abouelnaga, Mahmoud A Afifi, Alaa M Elhaddad (Children’s Cancer Hospital Egypt 57357, Cairo), Amany M Ali, e1336
Institute of Tropical Ophthalmology, Bamako), Foussenyi Traoré (Pediatric Oncology Service, Gabriel Toure Hospital, Bamako), Mauritania: Sidi Sidi cheikh (Ophthalmology department, Nounakhott Medical University, Nounakhott), Ekhtelbenina Zein (Assistante Hospitalat - Universitaire, Faculté de médecine de Nounakhott Medecin Oncopédiate, Centre National d'Oncologie, Nounakhott). Mexico: Graciela Gonzalez Perez, Alma Janeth Sanchez Orozco (Hospital Civil de Guadalajara, Guadalajara), Miriam Ortega-Hernández, Marco A Ramirez-Ortiz (Department of Ophthalmology Hospital Infantil de Mexico Federico Gómez, Mexico City), Mongolia: Tsengelmaa Chuluunhbat (National Center for Maternal and Children Health of Mongolia, Ulaanbaatar), Morocco: Elhassan Abdallah (Ophthalmology Department of Rabat, Mohammed V University, Rabat), Sarra Benmouloud (Department of Pediatric Oncology, University Hassan II Fès, Fès), Asmaa El Kettani (Centre Hospitalier et universitaire Ibn Roch, faculté de médecine et de pharmacie Universite Hassan 2, Casablanca), Laila Hessissen (Pediatric Hematology and Oncology Department of Rabat - Mohammed V University, Rabat). Mozambique: Rosdali Y Díaz Coronado, Arturo M Zapata López (Department of Pediatric Hematology-Oncology, University of Aveueles, University of Lausanne, Lausanne). New Zealand: Ruellyn L Crockforth, Yvonne Ng (Starchild Children’s Hospital Auckland), Jaume Catala-Mora, Guillermo L Chantada, Maria G Correa Llano (Vall d`Hebron, Barcelona), Julia Balaguer, Honorio Barranco (Pediatric Hematology-Oncology, Charlotte Mexeke Johannesburg Academic Hospital, Department of Clinical Medicine, University of Pretoria, Pretoria), Julie Wetter (Department of Radiation Oncology, University of Cape Town, Groote Schuur Hospital, Cape Town), Spain: Silvia Alarcón Portabella, Nieves Martin-Begue, Charlottesville Wollny Dod (Department of Pediatric Ophthalmology, Hospital Vall d’Hebron, Barcelona), Julia Balaguer, Honorio Barranco (Pediatric Hematology-Oncology, St Erik Eye Hospital, Stockholm). Switzerland: Maja Beck Popovic (Unit of Pediatric Hematology-Oncology, University Hospital CHUV, Lausanne), Francis L Munier (Jules-Gonin Eye Hospital, Fondation Asile de Aveugles, University of Lausanne, Lausanne). Sri Lanka: Sónia Silva (Centro Hospital Universitário de Coimbra, University of Coimbra, Coimbra), South Korea: Dong Hyun Jo (Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul), Jeong Hun Kim (Department of Ophthalmology, Seoul National University Hospital, Seoul). Romania: Codruta Comsa, Monica D Dragomir (Oncology Institute “Prof. Dr. Al. Trestioreanu”, Bucharest), Russian: Vladimir Nereov, Svetlana Saakyan (Moscow Helmholtz Research Institute of Eye Diseases, Moscow), Vladimir Polyakov, Tatiana I Ushakova (Head and Neck Tumors Department, SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center of Oncology of Russian Federation, and Medical Academy of Postgraduate Education, Moscow), Vera A Varoyava, Andrey A Varoyov (S.Fyodorov Eye Microsurgery General State Institution, Moscow). Rwanda: Tuyisabhe Théophile (Kabgayi Eye Unit, Gitarama), Saudi Arabia: Saleh Al Mesfer, Azza Maktabi (King Khalid eye specialist hospital, Riyadh), Saad Al Al-Dahmash, Hind M Alkait (College of Medicine, King Saud University, Riyadh). Senegal: Claude Moreira (Service d’oncologie pédiatrique de l’hôpital Ariste de l’dantec, Dakar), Paule Aida N’Doye Roth (Cheikh Anta Diop University of Dakar, Le Dantec Hospital, Dakar). Serbia: Vesna R Ilic, Marina Nikitovic (Institute for Oncology and Radiology, Belgrade), Slobodanka Latinovic (Clinical Center Of Vojojina – University Eye Clinic, Eye Research Foundation Vidar – Latinovic, Novi Sad). Singapore: Boon Long Quah, Deborah Tan (Singapore National Eye Centre and KK Women’s and Children’s Hospital in Singapore), Slavkina Stanislava, Hederova Kristina, Hussakova Silvia (Children’s Hospital, Bratislava), Slovenia: Alenka Lavric Groznik, Manca Tekavcic Pompe (Univ. Medical Centre Ljubljana, Univ.Eye Hospital Ljubljana, Ljubljana). South Africa: Alan Davidson (Red Cross Children’s War Memorial Hospital and the University of Cape Town, Cape Town), Magrittha Du Bruyn (University of KwaZulu-Natal, Durban), Johannes Du Plessis, David K Stones (Department of Paediatrics and Child Health, University of the Free State, Bloemfontein), Jennifer A Geel, Khumo H Moyo (Division of Paediatric Haematology-Oncology, Charlotte Meexke Johannesburg Academic Hospital, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Johannesburg), Marianna Kruger (Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch), Ismail Mayet, Gita Naidu, Natasha Naidu (University of the Witwatersrand, Johannesburg), Hamzah Mustak (Division of Ophthalmology, University of Cape Town, Cape Town), David Reynolds (University of Pretoria, Pretoria), Julie Wetter (Department of Radiation Oncology, University of Cape Town, Groote Schuur Hospital, Cape Town), Spain: Silvia Alarcón Portabella, Nieves Martin-Begue, Charlotte Wolley Dod (Department of Pediatric Ophthalmology, Hospital Vall d’Hebron, Barcelona), Julia Balaguer, Honorio Barranco (Pediatric Hematology-Oncology, University Hospital CHUV, Lausanne), Tamás Kadar (University of Szeged, Szeged), Zsófia Fekete (Pediatric Hematology-Oncology, University Children’s Hospital, Budapest). Sweden: Charlotte All-Eriksson, Katarina Bartum (ST Eye Hospital, Stockholm), Switzerland: Maja Beck Popovic (Unit of Pediatric Hematology-Oncology, University Hospital CHUV, Lausanne), Francis L Munier (Jules-Gonin Eye Hospital, Fondation Asile de Aveugles, University of Lausanne, Lausanne). Tunisia: Chouayba Houri, Djelloul A Salem, Assia Charfi, Nefissa Msaid (Medical Centre, Monastir, Tunisia), Chouayba Houri, Djamila Boudraa (University of Monastir, Monastir, Tunisia), Driss Hidajat (Department of Hematology and Oncology, University Hospital of Monastir, Monastir, Tunisia). UK: Anna Rogowska (Department of Ophthalmology, The Children’s Memorial Health Institute, Warsaw), Portugal: Guilherme Castela, Sônia Silva (Centro Hospital Universitário de Coimbra, University of Coimbra, Coimbra).
References

1. Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93: 1129–31.

2. Canturk S, Qaddoumi I, Khetan V, et al. Survival of retinoblastoma in less-developed countries: impact of socioeconomic and health-related indicators. Br J Ophthalmol 2010; 94: 1342–1346.

3. Fabian ID, Abdallah E, Abdullahi SU, et al. Global Retinoblastoma presentation and survival by national income level. JAMA Oncol 2020; 6: 685–695.

4. Bas Z, Dalvin LA, Tadepalli S, et al. Outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma based on patient age in 964 eyes of 554 patients. Asia Pac J Ophthalmol 2021; 10: 373–380.

5. Fabian ID, Stacey AW, Johnson KP, et al. Primary intravenous chemotherapy for group D retinoblastoma: a 13-year retrospective analysis. Br J Ophthalmol 2017; 101: 82–88.

6. Ueda T, Koga Y, Yoshikawa H, et al. Survival and ocular preservation in a long-term cohort of Japanese patients with retinoblastoma. BMC Pediatr 2020; 20: 37.

7. Waddell K, Matts M, Bidwell C, et al. A ten-year study of retinoblastoma in Uganda: an approach to improving outcome with limited resources. Cancer Epidemiol 2021; 71: 107777.

8. Sow AS, Ndoye Roth PA, Moreira C, et al. Treatment of retinoblastoma: Senegalese experience. J Fr Ophtalmol 2014; 37: 811–817 (in French).

9. Sah KP, Sajju R, Roy P, Kufle S. Retinoblastoma: ten years experience at Kanit's Children's Hospital, JNM J Nepal Med Assoc 2013; 52: 576–579.
10 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *Lancet* 2016; 388: e19–23.

11 Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014; 12: 1500–24.

12 Mallipatna AC, Galle BL, Chévez-Barrios P, et al. Retinoblastoma. In: Amin MB, Edge SB, Greene FL, et al, eds. *AJCC Cancer Staging Manual*, 8th edn. New York: Springer, 2017.

13 Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York, NY: Springer, 2003.

14 UN. World population prospects: The 2017 revision. 2017. https://population.un.org/wpp/publications/files/wpp2017_keyfindings.pdf (accessed May 25, 2022).

15 Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. *J Clin Epidemiol* 1999; 52: 1165–72.

16 Dimaras H, Khetan V, Halliday W, et al. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. *Hum Mol Genet* 2008; 17: 1363–72.

17 Tomar AS, Finger PT, Gallie B, et al. Global retinoblastoma treatment outcomes: association with national income level. *Ophthalmology* 2021; 128: 740–53.

18 Tomar AS, Finger PT, Gallie B, et al. A multicenter, international collaborative study for American Joint Committee on Cancer Staging of Retinoblastoma: part II: treatment success and globe salvage. *Ophthalmology* 2020; 127: 1713–46.

19 Ali AAE, Elsheikh SMA, Elloui A, et al. Clinical presentation and outcome of retinoblastoma among children treated at the National Cancer Institute (NCI) in Gezira, Sudan: a single institution experience. *Ophthalmic Genet* 2011; 32: 122–25.

20 Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. *Int J Clin Oncol* 2004; 9: 69–73.

21 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497–506.

22 Fabian ID, Stacey AW, Bowman R, et al. Retinoblastoma management during the COVID-19 pandemic: a report by the Global Retinoblastoma Study Group including 194 centers from 94 countries. *Pediatr Blood Cancer* 2021; 68: e28584.

23 WHO Global Initiative for Childhood Cancer. An overview. Nov 2, 2020. https://www.who.int/docs/default-source/documents/health-topics/cancer/who-childhood-cancer-overview-booklet.pdf (accessed Sept 21, 2021).

24 Fabian ID, Stacey AW, Foster A, et al. Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 318 patients from 40 European countries. *Br J Ophthalmol* 2021; 105: 1435–43.

25 Zhao J, Feng Z, Gallie BL. Natural history of untreated retinoblastoma. *Cancers* 2021; 13: 13.

26 Fabian ID, Khetan V, Stacey AW, et al. Sex, gender, and retinoblastoma: analysis of 4351 patients from 153 countries. *Eyes* 2021; published July 16. https://doi.org/10.1038/s41433-021-01675-y.

27 Bowman R. Retinoblastoma: a curable, rare and deadly blinding disease. *Community Eye Health* 2018; 31: 1–4.

28 Chantada G, Luna-Fineman S, Sitorus RS, et al. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. *Pediatr Blood Cancer* 2013; 60: 719–27.

29 Arora RS, Challinor JM, Howard SC, Israels T. Improving care for children with cancer in low- and middle-income countries—a SIOP PODC initiative. *Pediatr Blood Cancer* 2016; 63: 387–91.